Member Info for elrico

SP has for the last 6 years? However, I expect they will be correct in 2024.

https://x.com/lemminginvestor/status/1741125524435423561?s=46

Https://x.com/lemminginvestor/status/1741125524435423561?s=46

Hi Toyin,

You make the same mistake as I. You/I have regular phone chats and these can lead to thinking our POV is perfectly clear, when in fact the written word may suggest otherwise.

I have regular chats with PIs and often wrongly assume the written version to a wider audience is as clear as the phone calls.

Before anyone argues I show preferential treatment to certain people, I don't. I'll chat to anyone because I need all the friends, real or not, as I can muster. 🤗

Hi TC,

I understand that SA understands investor concerns. TW and I are unsure about their timeline and value. It's possible that the goal is to acquire two modest companies for the reasons provided, and then focus on the post-Croda/Sederma launch for the remaining acquisitions. I suspect this might be the case, and if it is, TW and some of us need to relax and keep a watchful eye. We should react to the news as it comes, rather than ahead of it. IMHO, too many people are assuming the acquisitions are going to be in a short period of time and create accessive dilution. This will not be the case. SA has previously stated the process will take into account the board's performance targets. Serious dilution impacts these, I, therefore, have confidence they will be stage-managed.

Hi Aquae,

I want to clarify my stance on the proposed acquisitions. I believe that you and I share the same understanding of the board's decision and the reasoning behind it, which SA explained in the last interview. From what has been made public, I don't have any issues with the first two acquisitions. They are expected to be profitable and will help in building a commercial profile. It will also benefit AxisBiotix in cross-selling. Furthermore, these acquisitions have a modest value, so I'm not worried about excessive dilution.

IF I am correct on the initial acquisition currently over 12 months down the road is the one I think it is, it will be one of the largest, and most accretive, even so, the value is not highly dilutive even if paid for with 100% SBTX shares. Again, IF it is the Company I think it is, it gives SBTX at least two access routes into the NHS with topical and wound care. If SA and Manprit pull this off there will be some hat-tipping and humble pie eaten.

Regarding Croda revenues, I am not making any assumptions about their delivery. Thus, I prefer larger acquisitions that can help mitigate excess dilution after the Croda revenues come in, especially if they are substantial. I am slightly concerned that the TW keeps mentioning £25m in revenues, as we have no guidance on the time it would take to achieve these numbers. I worry that the expectations for the first 12 months may be set too high and may come back to affect us, as these could be seen as the CEO's expectations. TW is correct, the figure is SA's based on c10% of Matrixl revenues, but I am sure SA is thinking three-plus years down the line.

Croda/Sederma could surprise us, and for this reason, I try not to second guess the market. Short-termism can do serious damage to PI's wealth.

Constantly dwelling on past events can be frustrating. However, we must acknowledge that the board needs to adapt to Croda's needs, not the other way around. If Croda presents a valid reason for adopting a more scientific validation process that benefits all parties involved, then it is our responsibility to accept it. We should refrain from blaming SA and the board for any delays in timelines. We investors chose to invest in an early-stage fledgling whose strategy is largely aligned with a global partner and accept who the dominant partner is. It is not SBTX.

Hi TC,

Insulting readers with a "Critically analyzing the reasons for the share price decline is not productive or helpful. We are all aware of the reasons behind the current state of the share price. These reasons have been previously discussed in my updates, including today, and also include my land mine prophecy. Surely, there is no need for me to elaborate further on this point, is there?

I never indicated TW had not made rational points; MY point was his delivery, along with what I hope are specific assumptions he makes without the details we need to make an informed decision. Again, this is something I have discussed in my 10.12.23 update.

I always try to be fair and balanced with my POV. I guess my Christian faith sometimes gets in the way of being angry and swearing because certain subscribers like that sort of thing, as TW, eludes. It isn't me; I am far more liberal than some people may think.

SA has made mistakes? Absolutely, and I'm sure he would acknowledge this. I even mentioned it in the last podcast when I referred to the buy-build strategy.

I talk to SA often. He is open to genuine criticism, but the hateful comments and being called a clown for clout are not productive or helpful. I will always strive to steer clear of such rhetoric.

There are two specific areas where TW and I are in agreement. The first is the timing of the buy-build, which I have already discussed with SA. The second is our shared expectations for the first acquisition. However, it's worth noting that since the details are not known to anyone outside the company, we are still making assumptions. SA was not willing to put his head on the block for masochistic perversions, he was confident for a reason. He said himself it would be "stupid." And yet!

I have no intention of being an SA apologist, this does provide no credibility for me and does not assist SA or SBTX in the future because investors will see right through it. I am who I am, I'm too set in my ways to change into Mr Angry. Bless him!

I think Mr Angry’s comments will prove a tad harsh. Time will tell. He makes some pertinent points but diminished with his language. Moreover, there a one or two assumptions which I discuss.

I suspect the “clown” will have the last laugh while we court jesters party.

https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-7f6

That's my deep thought for the year end.

Have a Fab Christmas, everyone. Yes you too, Mol, Skid, and Specsavers!

Meaning of Life is to enjoy it. Scoring childish points is now part of it? 🤡

Happy Christmas, Grinch!

Really, Mol!

Wow! It was a figure of speech not intended to be taken literally. 🙈

Come Al, you are no fool, please stop posting like one.

"Also the beauty parade, what was Sedermas customers responses, and how many have expressed very serious interest."

"Our product is well copyright protected so why any secrecy.. Also have good factual answers to these questions will enable investors to draw more exact timelines on income stream, because the huge issue with axis was the terrible sales numbers..at least with Croda we know current turnover as it already commands a huge market share."

It has already been explained to you in person at the Manchester event; SA has no control over what Croda is willing to share publicly. Croda's first concern is to protect its partnership with other big names in the industry, some of which are as big as Croda itself. They will be competing with these VIPs in the market, all eager to gain a first-mover advantage. Considering the crazy competition that exists in the skincare industry during the launch of a new product, why would you want to alert a competitor?

I'm sure SA knows far more than anyone he trusts to share because he is protecting his Company and its reputation.

Al,

Trying to second-guess a PLC acquisition playbook is futile. Most people I speak to think Croda bought Sederma to get its hands on Matryxl. The truth is that Matryxl came three years after the Croda acquisition. The Uniqema from ICI in 2006, suggests an evolving strategic move into skincare.

If I had to make an educated guess, I think Croda would be interested in observing how consumers respond to their purchasing power with a new product range with a new active ingredient. They will probably choose to sell their products at a higher price point if they receive a positive response from consumers, regardless of whether they have enough resources or not. This will be compelling data for Croda. They have an agreement with SBTX for the life of the patent which is 20 years from 2019. Why would Croda rush?

Toyin is spot on with his understanding of the royalty agreement. However, the price point indicated will be higher based on the additional enhancements. This came from Croda, not SA.

Al,

I am not taking the P out of you. You'll know what I mean when you read it back. I have fallen into your way of speaking. I am blaming it on the time. :)

Mad, are you mad? Only joking.

Investors like myself have been diligently building stakes for the future, drawing confidence from the distinguished scientific work at the University of Manchester, especially the contributions of Professor Catherine O'Neill and Professor Andrew McBain. The addition of Stuart Ashman and Manprit Randhawa to our partnership team, known for their successful buy-build approach, promises exciting developments ahead, although the full impact of their efforts remains to be seen.

Setting aside the Croda/Sederma partnership, which in itself is a strong reason for long-term investment in SBTX, there's a need to address the clarity of our acquisition strategy as communicated in recent RNS announcements-something I made clear in our last interview. It's evident that there has been a shift in the timelines for our first acquisition from last year to the end of this calendar year. We have a basic understanding why-however, legalities prohib expansion until the time is right. An adjustment that has inadvertently affected investor confidence. Rebuilding this confidence will understandably take some time and greater transparency.

In the interim, and until there is more clarity on the strategy, I expected that some investors might adopt a cautious stance, while others might be considering the opportunity to invest post-calendar year-end, especially if our first acquisition extends into 2024. Delays in such processes, although frustrating, are not uncommon and can occur for a variety of reasons.

I have complete faith Stuart and Manprit will deliver the "transformative" result and fully intend to be fully invested for the eventuallity. That said, even my confidence has bruises.

It appears there might be a bit of misunderstanding regarding our M&A strategy. Stuart has provided clear guidance on this matter, so it's surprising that there's still some confusion. The strategy encompasses more than just augmenting AxisBiotix sales. It's also about enhancing our board's leverage in distribution agreement negotiations and reducing our dependency on hurried deal-making due to financial constraints. Acquiring companies with established products is a strategic move that saves time, money, and resources, while simultaneously securing growth and stability.

Do the math

https://twitter.com/LEMMINGINVESTOR/status/1735112193245348080

Sikhthetech aka stt1

I can rewrite the text as follows:

Don't hesitate to admit your mistakes. Since September/October 2014, you have been consistently wrong about the merits of your favourite company. We all make mistakes from time to time, but being wrong for 13 years is quite remarkable. It's a pity that you weren't short, that would have been really impressive.

#SPSY Spectra Systems' strategic acquisition of Cartor - a game-changer in high-security printing! Market cap soaring from £82M to £88.4M, reflecting confidence in this bold move. https://tinyurl.com/2mpmshs3

Hit the dam submit in error.

I'm fairly confident OPTI products were listed in the top 25 products very quickly. They have a Prime account listing.

Unfortunately, when searching using the correct spelling of the products, no result!

https://www.amazon.co.uk/s?k=axisbiotix&crid=YYPVFDZ6JAQ8&sprefix=axisbiotix%2Caps%2C84&ref=nb_sb_noss_2

Psoriasis - again, no AxisBiotix listing

https://www.amazon.co.uk/s?k=psoriasis+treatment&crid=1CO6WKPO9YZ4G&sprefix=psoriasis+%2Caps%2C84&ref=nb_sb_ss_ts-doa-p_4_10

IMHO, it's must be on Prime otherwise it won't get noticed.